Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

1.

[Prediction of gemcitabine treatment discontinuation based on platelet count before first administration].

Taniguchi R, Tokutome A, Matsunami J, Azuma S, Katsuragawa M, Hirata R, Sato Y, Kobayashi R, Hashimoto Y, Meguro K, Shibanami A, Okamura K, Miyakawa H, Tsumaki R.

Gan To Kagaku Ryoho. 2010 Nov;37(11):2105-8. Japanese.

PMID:
21084808
[PubMed - indexed for MEDLINE]
2.

Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.

Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, Alberts S, O'Dwyer P, Haller D, Catalano P, Cella D, Benson AB 3rd.

J Clin Oncol. 2009 Aug 10;27(23):3778-85. doi: 10.1200/JCO.2008.20.9007. Epub 2009 Jul 6. Erratum in: J Clin Oncol. 2009 Dec 1;27(34):5859.

PMID:
19581537
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Single agent gemcitabine chemotherapy in dogs with spontaneously occurring lymphoma.

Turner AI, Hahn KA, Rusk A, Gamblin RM, Cosgrove SB, Griffice K, Khanna C.

J Vet Intern Med. 2006 Nov-Dec;20(6):1384-8.

PMID:
17186854
[PubMed - indexed for MEDLINE]
4.

Surgical resection deteriorates gemcitabine-induced leukopenia in pancreatic cancer.

Onoue M, Terada T, Okuda M, Fujimoto K, Doi R, Imamura M, Inui K.

Int J Clin Oncol. 2004 Jun;9(3):174-8.

PMID:
15221601
[PubMed - indexed for MEDLINE]
5.

Toxicities of gemcitabine in patients with severe hepatic dysfunction.

Teusink AC, Hall PD.

Ann Pharmacother. 2010 Apr;44(4):750-4. doi: 10.1345/aph.1M587. Epub 2010 Mar 16.

PMID:
20233917
[PubMed - indexed for MEDLINE]
6.

Rapid reduction of platelet numbers in thrombocytosis.

Liumbruno G, Centoni PE, Ceretelli S, Sodini ML.

Ther Apher. 2000 Oct;4(5):374-6.

PMID:
11111819
[PubMed - indexed for MEDLINE]
7.

Unexpected severe myelotoxicity of gemcitabine in pretreated breast cancer patients.

Locker GJ, Wenzel C, Schmidinger M, Gnant MF, Marosi C, Jakesz R, Zielinski CC, Steger GG.

Anticancer Drugs. 2001 Mar;12(3):209-12.

PMID:
11290868
[PubMed - indexed for MEDLINE]
8.

Gemcitabine as first-line chemotherapy in elderly patients with unresectable pancreatic carcinoma.

Yamagishi Y, Higuchi H, Izumiya M, Sakai G, Iizuka H, Nakamura S, Adachi M, Hozawa S, Takaishi H, Hibi T.

J Gastroenterol. 2010 Nov;45(11):1146-54. doi: 10.1007/s00535-010-0258-9. Epub 2010 Jun 15.

PMID:
20549255
[PubMed - indexed for MEDLINE]
9.

Identification of a predictive biomarker for hematologic toxicities of gemcitabine.

Matsubara J, Ono M, Negishi A, Ueno H, Okusaka T, Furuse J, Furuta K, Sugiyama E, Saito Y, Kaniwa N, Sawada J, Honda K, Sakuma T, Chiba T, Saijo N, Hirohashi S, Yamada T.

J Clin Oncol. 2009 May 1;27(13):2261-8. doi: 10.1200/JCO.2008.19.9745. Epub 2009 Mar 16.

PMID:
19289617
[PubMed - indexed for MEDLINE]
10.

Meta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone.

Xie DR, Liang HL, Wang Y, Guo SS, Yang Q.

World J Gastroenterol. 2006 Nov 21;12(43):6973-81.

PMID:
17109519
[PubMed - indexed for MEDLINE]
Free Article
11.

Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levels.

Pollera CF, Ceribelli A, Crecco M, Oliva C, Calabresi F.

Invest New Drugs. 1997;15(2):115-21.

PMID:
9220290
[PubMed - indexed for MEDLINE]
12.

Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15.

Cortesi E, Ramponi S, Corona M, Moscetti L, Grifalchi F, Oliva A, Lembo A, Gasperoni S, Padovani A.

Lung Cancer. 2001 Feb-Mar;31(2-3):271-6.

PMID:
11165407
[PubMed - indexed for MEDLINE]
13.

[Changes in tumor marker levels as a predictor of gemcitabine effect on patients with unresectable or recurrent pancreatic cancer].

Tendo M, Nakata B, Nishino H, Inoue M, Kosaka K, Amano R, Yamada N, Hirakawa K.

Gan To Kagaku Ryoho. 2005 Jun;32(6):795-8. Japanese.

PMID:
15984518
[PubMed - indexed for MEDLINE]
14.

Third-line gemcitabine monotherapy for platinum-resistant advanced urothelial cancer.

Soga N, Kise H, Arima K, Sugimura Y.

Int J Clin Oncol. 2010 Aug;15(4):376-81. doi: 10.1007/s10147-010-0071-8. Epub 2010 Mar 24.

PMID:
20333430
[PubMed - indexed for MEDLINE]
15.

Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.

Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, Cigolari S, Testa A, Maiello E, Lopez M.

Cancer. 2002 Feb 15;94(4):902-10.

PMID:
11920457
[PubMed - indexed for MEDLINE]
Free Article
16.

Factors predicting the appearance of neutropenia in patients with advanced pancreatic cancer undergoing gemcitabine therapy.

Yoneyama K, Katsumoto E, Kurihara T, Kogo M, Ikegami A, Imawari M, Shimada K, Yoshikumi H, Inoue K, Kiuchi Y.

Hepatogastroenterology. 2012 May;59(115):894-8. doi: 10.5754/hge11567.

PMID:
22024222
[PubMed - indexed for MEDLINE]
17.

[Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].

Gong JF, Zhang XD, Li J, Di LJ, Jin ML, Shen L.

Ai Zheng. 2007 Aug;26(8):890-4. Chinese.

PMID:
17697554
[PubMed - indexed for MEDLINE]
18.

Gemcitabine-induced peripheral edema: report on 15 cases and review of the literature.

Azzoli CG, Miller VA, Ng KK, Krug LM, Hensley ML, O'Reilly EM, Muller RJ, Kris MG.

Am J Clin Oncol. 2003 Jun;26(3):247-51. Review.

PMID:
12796593
[PubMed - indexed for MEDLINE]
19.

[Two cases of advanced pancreatic cancer responding to gemcitabine with long survival of 2 years].

Yajima T, Furukawa Y, Ishii Y, Hattori Y, Matsumoto N, Yamamoto M, Yamaoka Y, Fujihara M, Fujita M, Kuniki H.

Gan To Kagaku Ryoho. 2004 Jun;31(6):953-7. Japanese.

PMID:
15222120
[PubMed - indexed for MEDLINE]
20.

Effect of low-dose gemcitabine on unresectable pancreatic cancer in elderly patients.

Matsumoto K, Miyake Y, Kato H, Kawamoto H, Imagawa A, Toyokawa T, Nakatsu M, Ando M, Hirohata M, Yamamoto K.

Digestion. 2011;84(3):230-5. doi: 10.1159/000330384. Epub 2011 Aug 23.

PMID:
21860243
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk